Alerta

生物传感元件、生物传感器及生物检测芯片

Resumen de: WO2026153209A1

A biosensing element. The biosensing element comprises: a substrate, and a thin film transistor and a reaction chamber which are located on one side of the substrate. The thin film transistor comprises: a gate, a gate insulating layer, an active layer, a source and a drain which are stacked. The thin film transistor is located in the reaction chamber, and antibodies are provided in the reaction chamber. The thin film transistor further comprises a protective layer including at least one of a first protective layer and a second protective layer, wherein the first protective layer is located between the gate insulating layer and the active layer, the second protective layer comprises a first portion that is located on the side of the part of the active layer exposed by the source and the drain away from the substrate, and a water contact angle of a material of the protective layer is greater than that of a material of the gate insulating layer.

ANTI-TAU MTBR ANTIBODIES AND METHODS TO DETECT CLEAVED FRAGMENTS OF TAU AND USES THEREOF

Resumen de: US20260201023A1

0000 Provided herein are antibodies, or fragments thereof, that specifically bind to a microtubule-binding region (MTBR) of tau, and uses thereof. Further provided are methods of detecting species of MTBR in blood or cerebral spinal fluid, and the use of such detection for diagnosing, prognosing, or staging pathological features and/or clinical symptoms of tauopathies, and to choose treatments appropriate for a given disease stage.

METHODS AND MATERIALS FOR MEASURING COMPLEMENT ACTIVATION

Resumen de: AU2025215582A1

The present disclosure provides, e.g., signature peptide compounds corresponding to various full-length protein components of the complement enzymatic cascade (e.g., C1q, C1s, C3, C3p, C4, C4p, C5, C5p, FB, and FBp). In one aspect, the invention relates to using these signature peptides for measuring and/or monitoring activation of the complement pathway, e.g., in clinical samples, such as plasma, serum, CSF, aqueous humor, or vitreous humor.

EARLY DIAGNOSIS SYSTEM UTILIZING STANDARD DEVIATION AND AUTOCORRELATION OF DYNAMIC FLUORESCENT OR X-RAY

Resumen de: US20260202426A1

0000 The present disclosure relates to a method of detecting a molecule associated with the diagnosis of a disease through movement of the molecules after fluorescent labeling or by using dynamic X-rays. A method of detecting a molecule associated with the diagnosis of a disease through movement of the molecules after fluorescent labeling or labeling with a crystalline plane, according to an aspect, enables large-scale imaging and Z-axis imaging, and thus can be effectively used in the field of diagnosis.

ANTI-CD103 ANTIBODIES

Resumen de: US20260201041A1

0000 The present invention relates to anti-CD103 antibodies, as well as use of these antibodies in diagnosis, prognosis, monitoring, and treatment of diseases.

Novel Molecules for Therapy and Diagnosis

Resumen de: US20260201026A1

0000 The present invention relates to novel molecules that can be employed for the prevention, alleviation, treatment and/or diagnosis of diseases, disorders and abnormalities associated with alpha-synuclein (α-synuclein, A-synuclein, aSynuclein, A-syn, α-syn, aSyn, a-syn) aggregates, including, but not limited to, Lewy bodies and/or Lewy neurites, such as Parkinson's disease, Multiple System Atrophy, Lewy Body dementia (LBD; dementia with Lewy bodies (DLB) (“pure” Lewy body dementia), Parkinson's disease dementia (PDD)) or Diffuse Lewy Body Disease. The invention relates to alpha-synuclein binding molecules, in particular to alpha-synuclein antibodies or an antigen-binding fragment or a derivative thereof and uses thereof. The present molecules can also be used for determining a predisposition to such a disorder, disease or abnormality, monitoring residual disorder, disease or abnormality, or predicting the responsiveness of a patient who is suffering from such a disorder, disease or abnormality to treatment with a certain medicament.

COMPOUNDS FOR TAU PROTEIN DEGRADATION

Resumen de: US20260199318A1

Provided herein are bifunctional compounds that bind tau protein and/or promote targeted ubiquitination for the degradation of tau protein. In particular, provided are compounds that can bind tau protein a protein whose aggregation is implicated in a variety of neurodegenerative disease (e.g., tauopathies), and can promote its degradation by recruiting an E3 ubiquitin ligase (e.g., Cereblon), which can ubiquitinate tau protein, marking it for proteasonmal degradation. Also provided are radiolabeled forms of the bifunctional compounds, pharmaceutical compositions comprising the bifunctional compounds, methods of detecting and/or diagnosing neurological disorders, methods of detecting and/or diagnosing pathological aggregation of tau protein (e.g., in the central nervous system), methods of treating and/or preventing neurological disorders, and methods of promoting the degradation of tau protein by E3 ubiquitin ligase activity in a subject by administering a compound or composition described herein.

FFA1 (GPR40) AS A THERAPEUTIC TARGET FOR NEURAL ANGIOGENESIS DISEASES OR DISORDERS

Resumen de: US20260199341A1

The instant invention provides methods and compositions related to discovery of Free Fatty Acid Receptor 1 (FFA1) as a therapeutic target for treatment or prevention of diseases or disorders of neurons that are characterized by angiogenesis, or of vascular diseases of the eye, retinal degeneration and/or tumors more generally. Therapeutic and/or prophylactic uses and compositions of known FFA1 inhibitors, including small molecules and nucleic acid agents, are described. Methods for identification of novel FFA1 inhibitors are also provided.

DE NOVO DESIGNED PROTEIN BINDERS TO NATIVE FLEXIBLE HELICAL PEPTIDES

Resumen de: US20260201015A1

0000 Target-binding polypeptide are disclosed that include an amino acid sequence at least 50% identical to the amino acid sequence selected from the group consisting of SEQ ID NO:1-12, nucleic acids encoding such polypeptides, and methods for use of the polypeptides in detecting binding of the target and correlating binding to the target with a disease state.

METHODS OF PREDICTING AND TREATING IMMUNOTHERAPY ADVERSE EVENTS BASED ON IMMUNE CELL POPULATIONS

Resumen de: US20260202406A1

0000 The present disclosure generally relates to compositions and methods for predicting or diagnosing immune-related adverse events (irAE) before, during, or after immune checkpoint inhibitor (ICI) treatment in a subject with cancer. The method includes assessment of abundance or expression of immune cells, autoantibodies, and/or cytokines.

MULTIPLE SFLT-1 MEASUREMENTS FOR PROGNOSIS OF EARLY ONSET PREECLAMPSIA

Resumen de: US20260202422A1

The invention relates to a method of treatment for early onset preeclampsia in a pregnant subject, including determining a level of soluble fms-like tyrosine kinase-1 (sFlt-1) or fragment(s) thereof in a sample that has been isolated from said pregnant subject. The invention further relates to the combined measurement of sFlt-1 and PlGF, The invention relates further to a kit for carrying out the method of the invention, including detection reagents for determining the level sFlt-1 or fragment(s) thereof, and optionally for determining the level of at least one additional biomarker, in a sample from a subject.

METHODS AND COMPOSITIONS FOR PREDICTING AND TREATING TRIPLE NEGATIVE BREAST CANCER

Resumen de: US20260201473A1

0000 Biomarkers that can be used for the detection or diagnosis of disease states, preferably cancer (e.g., triple negative breast cancer (TNBC)) disease states, to the prediction of disease prognosis and/or a treatment outcome, to the identification of a treatment regimen for cancer (e.g., TNBC), and/or to indicate the responsiveness to the treatment regimen for cancer (e.g., TNBC) in a subject are described. Also described are probes capable of detecting the biomarkers and related methods and kits for determining cancer (e.g., TNBC) disease states and/or identification of treatment regimens for the cancer (e.g., TNBC) disease states.

A HETEROHYBRIDOMA-BASED METHOD OF GENERATING RECOMBINANT RABBIT MONOCLONAL ANTIBODIES AND ANTIBODIES PRODUCED BY METHOD

Resumen de: US20260201046A1

Provided is a heterohybridoma-based method of generating recombinant rabbit monoclonal antibodies, recombinant anti-IL-6 receptor-alpha (IL-6Rα) antibodies generated using such methods, and immune assay methods kits employing such antibodies.

POTENCY ASSAY FOR PHARMACEUTICAL PRODUCTS

Resumen de: US20260202397A1

0000 The present invention describes a method for assessing the potency of a pharmaceutical product assumed to be effective in treating a disorder, preferably a genetic disorder or a non-genetic disorder, wherein the disorder results in an impaired functionality of a physiological bodily function of a subject having the disorder, wherein the method comprises: (i) incubating an engineered tissue with the pharmaceutical product, wherein the engineered tissue is or has been modified to be representative for the disorder; (ii) determining at least one physical parameter of the engineered tissue resulting from step (i), wherein the physical parameter is a measure of the functionality of the physiological bodily function, and (iii) determining whether a value of the at least one physical parameter determined in step (ii) meets a predetermined threshold of said physical parameter, which determines whether the pharmaceutical product has potency, wherein, if said value of the at least one physical parameter exceeds the predetermined threshold, potency of the pharmaceutical product is indicated for treating the disorder by at least partially restoring the functionality of the physiological bodily function.

LIGANDS SPECIFIC FOR ASCT1

Resumen de: US20260200988A1

Polypeptides capable of specifically recognizing and binding to the neutral amino acid transporter ASCT1/SLC1A4, while not binding to the related neutral amino acid transporter ASCT2/SLC1A5. Also, both in vitro and in vivo methods of specifically detecting or/and measuring the level of ASCT1, and to the use of said polypeptides in diagnosis and therapy.

METHODS FOR IDENTIFYING DISEASE-ASSOCIATED RNA AND RNA BINDING PROTEIN (RBP) INTERACTIONS FOR DIAGNOSIS AND TREATMENT SELECTION

Resumen de: AU2024395871A1

The present disclosure provides methods for simultaneously identifying dynamic and disease-associated RNA binding protein (RBP)-RNA interaction (PRI) sites at single nucleotide resolution across the entire transcriptome. The methods disclosed herein recapitulates PRI profiles obtained with several distinct conventional PRI methods in a single assay at efficiencies that are improved by orders of magnitude, and permit the identification of the specific RBP bound at a PRI.

ANTIBODIES WITH FC MODIFICATIONS AND METHODS OF USING THE SAME

Resumen de: AU2024388350A1

The disclosure features anti-tumor necrosis factor receptor superfamily (TNFRSF), anti-tumor necrosis factor superfamily (TNFSF), anti-CD28, and anti-ICOS antibodies and antigen-binding fragments thereof with amino acid modifications at the Fc domain, and the use of these antibodies or antigen-binding fragments to modulate immune response. The antibodies and antigen-binding fragments thereof can be used to treat a wide variety of cancers, autoimmune disorders, neurological disorders, infectious diseases, inflammatory diseases, and transplant rejections.

NANOBODY AGAINST γ-AMINOBUTYRIC ACID TYPE B RECEPTOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF

Resumen de: WO2026149125A1

Provided are a nanobody against γ-aminobutyric acid type B receptor, and a preparation method therefor and the use thereof. The nanobody can specifically recognize and bind to the γ-aminobutyric acid type B receptor, exhibits a good affinity therefor, and can be used in the preparation of a product for diagnosing, preventing or treating diseases or conditions associated with the γ-aminobutyric acid type B receptor, or for detecting the presence or level of the γ-aminobutyric acid type B receptor in a sample.

CELL TYPE - ANTIGEN MARKER DETECTION IN CELL SAMPLES FROM THOSE SUSPECTED OF MCI OR ALZHEIMER'S DISEASE

Resumen de: WO2026151791A1

Provided herein are systems, kits, and methods for cell type-antigen marker (CTA marker) detection in cell samples (e.g., blood or CSF) from those suspected of having pre-clinical AD (Pre-AD) or mild cognitive impairment (MCI) or dementia from Alzheimer's Disease. In certain embodiments, such CTA marker detection is quantitative, gender specific, employs at least two gender-specific CTA markers in Figure 7C, and/or employs a mass cytometer (e.g., where mass-labeled antigen binding agents are mixed with the cell-sample). In some embodiments, at least some of the CTA markers are: i) unhealthy CTA markers which are generally upregulated in subjects with Pre-AD or MCI or dementia from Alzheimer's disease, and/or ii) healthy CTA markers which are generally down regulated in subjects with Pre-AD or MCI or Alzheimer's disease. In particular embodiments, the unhealthy CTA markers, and any healthy CTA markers employed, are used for determining a subject's risk of having or developing Pre-AD or MCI or dementia from Alzheimer's disease (e.g., by generating a score).

GLS1 DIAGNOSTIC METHODS

Resumen de: WO2026151983A1

Aspects of the disclosure relate to compositions and methods for modulating levels, transcription, splicing, and/or translation of one or more RNA transcripts (e.g., mRNA transcripts) in a cell or subject. The disclosure is based, in part, on methods of identifying a subject of having or being at risk of developing a disease or disorder associated with dysregulated glutamine levels, such as a subject having a mutation that affects glutaminase (GLS1), which is an enzyme responsible for producing glutamate from glutamine. In some embodiments, compositions and methods of the disclosure are useful for treating a psychiatric disorder (e.g., depression (DEP), major depressive disorder (MDD), bipolar disorder (e.g., BPD1, BPD2), mania (MAN), psychosis (PSY), schizophrenia (SCZ), schizoaffective disorder (SZA), or post-traumatic stress disorder (PTSD)) and/or a disease associated with dementia, such as Alzheimer's disease.

MEDICAL DIAGNOSIS, PROGNOSIS AND PREDICTION OF TREATMENT USING MULTIPLEXED SIGNATURES

Resumen de: WO2026151932A1

The present disclosure relates to diagnosis, prognosis, and prediction of treatment outcomes of neuropathological conditions.

METHODS AND SYSTEMS FOR PREPARING AND ANALYZING SAMPLES FOR EXTRACELLULAR VESICLE BIOMARKERS ASSOCIATED WITH BRAIN-RELATED CONDITIONS OR DISORDERS

Resumen de: WO2026151876A1

Disclosed herein are embodiments related to analyzing brain-derived extracellular vesicles (EVs). Some methods described herein comprise: (a) enriching a biological sample for brain-derived EVs, the biological sample being from a subject having a brain-related condition or disorder and comprising the brain-derived EVs; (b) subjecting the enriched sample to EV disruption to produce an analytic sample; (c) purifying the analytic sample to capture EV material after the EV disruption; and (d) analyzing the captured EV material to determine a differential amount of the captured EV material relative to a control. The method allows for improving 10 outcomes for patients suffering from brain-related conditions or disorders.

PHARMACEUTICAL COMPOSITION AND SCREENING METHOD

Resumen de: WO2026150914A1

This pharmaceutical composition for use in the treatment of patients with diseases associated decreased ATP levels comprises the DNA or mRNA of at least one molecule selected from the group consisting of PI3Kα, IGFBP1, EIF2S2, OCIAD2, MANF, and GAPDHS.

β－カテニンデポの検出及び調節アッセイ

Resumen de: WO2025014769A1

The present application provides, in some aspects, methods of assaying for β-catenin depots, and uses thereof, such as to identify a compound that modulates, such as increases, the β-catenin depots in a cell. In other aspects, also provided herein are associated methods (such as methods of identifying a compound useful for treating a β-catenin associated disease), kits, and useful compounds identified therefrom.

METHOD OF PROVIDING EARLY INTERVENTION TO A NEWBORN OR INFANT WITH AUTISM SPECTRUM DISORDER

Nº publicación: US20260202427A1 16/07/2026

Solicitante:

THE TRUSTEES OF COLUMBIA UNIV IN THE CITY OF NEW YORK [US]
THE REGENTS OF THE UNIV OF CALIFORNIA [US]
The Trustees of Columbia University in the City of New York
The Regents of the University of California

Resumen de: US20260202427A1

0000 Described is use of biomarkers found in maternal mid-gestation (MMG) and cord blood (CB) plasma for early identification of children with autism spectrum disorder (ASD) or at risk for ASD. Using these biomarkers, newborns and infants with ASD or at high risk of ASD can be identified and interventions for ASD, which have been shown to be effective early in life, can be provided to a child as young as a newborn.